Stemline Therapeutics (STML) Misses Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. SPY
7. CVS
8. UNH
9. TMUS
10. LMT

Go back to Stemline Therapeutics (STML) Misses Q1 EPS by 1c

Stemline Therapeutics Reports First Quarter 2015 Financial Results

May 11, 2015 8:01 AM EDT

NEW YORK, May 11, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical stage biopharmaceutical company developing novel drugs targeting cancer stem cells (CSCs) and tumor bulk, today reported financial results for the quarter ended March 31, 2015.

Ivan Bergstein, M.D., Stemline's Chief Executive Officer, commented, "Stemline continues to execute on its strategic goals of advancing its pipeline. We remain on track to complete the lead-in stage mid-year, and continue patient accrual, in our pivotal trial of blastic plasmacytoid dendritic cell neoplasm, BPDCN. We are also conducting clinical studies with SL-401 in additional hematologic... More